
# An Overview of the COVID-19 situation: Lesson Learnt from Iran

Feb 28, 2022

Kamiar Alaei, MD, DrPH

# Structure of Health System in Iran



# Health Facilities

Source: Ministry of Health, Iran; Dr. Malekzadeh; July


\*S. Alireza MARANDI; The Health Landscape of the Islamic Republic of Iran; Medical Journal of Islamic World Academy of Sciences


Year	Health Facilities	Pharmacy Public and private	Laborator ies Public and private	Hospital beds per 1000 people	Total hospital beds	Iranian Physicians	Physicians per 1000 people	Medical School *	Teaching hospital beds*
1978	2,420	865	1,088	1.5	56,000	15,000	0/41	9	9,558
1988	3,175	1,621	1,928	1.4	77,000	21,500	0/34		
1992	3,809	2,026	2,923	1.6	91,000	32,500	0/43		
2018*	7,440	12,000	5,700	1.6 (2.8 in Turkey)	130,058 (16% private/ charity)	97,028	1.2 (1.8 in Turkey)	80	53,902

vaccine coverage from 7% - 33% in 1980 to over 97% -100% in 2017 nationwide (WHO), by using Behvarz in the country, especially in the rural area

From 2001, Iran has obtained the certificate of **polio eradication** and sustained this success.


Vaccines 2	017 2	016 2	015 2	014 2	013 2	012 2	011 2	010 2	009 2	2008 2	2007	2006 2	2005 2	004	2003	2002	2001	2000 1	1999 1	1998	1997	1996	1995	1990	1985	1980
BCG	99	99	99	99	99	99	99	99	99	99	99	99	99	99	99	97	91	99	99	99	91	96	96	95	79	7
DTP1	99	99	99	99	98	99	99	99	99	99	99	98	97	99	99	99	96	99	99	99	99	99	98	97	75	57
DTP3	99	99	98	99	98	99	99	99	99	99	99	98	95	99	99	99	96	99	99	99	99	99	98	91	51	32
HepB3	99	99	98	99	99	98	99	99	99	99	97	98	94	95	98	99	94	99	95	94	93	84	59	_	_	_
HepB_BD	95	95	96	97	99	96	99	99	99	99	99	99	96	99	99	99	94	99	_	_	_	_	_	_	_	_
Hib3	99	99	98	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_
IPV1	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_
MCV1	99	99	99	99	98	98	99	99	99	98	97	99	94	96	99	99	96	99	99	99	95	99	95	85	62	39
MCV2	98	98	98	98	97	97	99	99	99	96	97	98	92	99	96	96	94	99	_	_	_	_	_	_	_	_
PCV3	_	-	_	-	-	_	-	-	-	-	-	_	_	-	_	-	_	_	_	-	_	-	_	_	_	_
Pol3	99	99	98	99	98	99	99	99	99	99	98	99	95	98	99	99	95	99	99	99	99	99	97	90	63	38
RCV1	99	99	99	99	98	98	99	99	99	98	97	99	94	96	_	-	_	_	_	_	_	_	_	_	_	_
RotaC	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_	_
Diseases	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005 2	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1990	1985	1980
Diphtheria	2017 2	2016 10	2015 28	2014 13	2013 190	2012 150	2011 2 132	2010 : 106	2009 58	2008 52	<b>2007</b> 32	2006 2 26	2005 2 15	2 <b>004</b> 6	2003 24	2002 10	<b>2001</b> 15	2000 18	1999 13	1998 13	1997 30	1996 13	<b>1995</b> 9	<b>1990</b> 373	<b>1985</b> 143	<b>198</b> (
Diphtheria Japanese	2																									
Diphtheria	2													6	24	10	15		13		30	13	9	373		139
Diphtheria Japanese encephalitis	2	10	28 -	13	190	150	132	106	58	52 -	32	26 _	15 _	6	24	10	15 - 9'582	18	13	13	30	13	9	373	143	139
Diphtheria Japanese encephalitis Measles Mumps Pertussis	2	10	28 -	13 - 99 -	190 - 189 -	150	132	106	58 - 262 - 590	52 - 127 - 605	32 - 133 - 267	26 - 220 - 89	15 - 7 - 125	6 - 3 - 98	24 - 11'644 - 81	10 - 9'554 - 21	15 - 9'582 - 112	18 - 11'874 10'417 94	13 - 4'137 : - 24	13	30 - 3'901 - 50	13 - 2'329 - 80	9 - 263 - 45	373 - 5'341 :	143 — 20'582 — 11'519	139 - 31'130 - 20'395
Diphtheria Japanese encephalitis Measles Mumps Pertussis Polio	2 51 - 14 0	10 - 82 - 116 0	28 - 615 - 145 0	13 - 99 - 115 0	190 - 189 - 1'415	150 - 332 - 1'329 0	132 - 73 - 650 0	106 - 538 - 464 0	58 - 262 - 590 0	52 - 127 - 605 0	32 - 133 - 267 0	26 - 220 -	15 - 7 -	6 - 3	24 - 11'644 -	10 - 9'554 -	15 - 9'582 -	18 - 11'874 10'417 94 3	13 - 4'137	13 - 2'869 -	30 - 3'901 -	13 - 2'329 -	9 - 263 -	373 - 5'341 :	143 - 20'582	139 - 31'130 -
Diphtheria Japanese encephalitis Measles Mumps Pertussis Polio Rubella	2 51 - 14	10 - 82 - 116	28 - 615 - 145	13 - 99 - 115	190 - 189 - 1'415	150 - 332 - 1'329	132 - 73 - 650	106 - 538 - 464	58 - 262 - 590	52 - 127 - 605	32 - 133 - 267	26 - 220 - 89	15 - 7 - 125	6 - 3 - 98	24 - 11'644 - 81	10 - 9'554 - 21	15 - 9'582 - 112	18 - 11'874 10'417 94	13 - 4'137 : - 24	13 - 2'869 - 20	30 - 3'901 - 50	13 - 2'329 - 80	9 - 263 - 45	373 - 5'341 : - 1'230	143 — 20'582 — 11'519	139 - 31'130 - 20'395
Diphtheria Japanese encephalitis Measles Mumps Pertussis Polio	2 51 - 14 0	10 - 82 - 116 0	28 - 615 - 145 0	13 - 99 - 115 0	190 - 189 - 1'415	150 - 332 - 1'329 0	132 - 73 - 650 0	106 - 538 - 464 0	58 - 262 - 590 0	52 - 127 - 605 0	32 - 133 - 267 0	26 - 220 - 89	15 - 7 - 125	6 - 3 - 98	24 - 11'644 - 81	10 - 9'554 - 21	15 - 9'582 - 112	18 - 11'874 10'417 94 3	13 - 4'137 : - 24	13 - 2'869 - 20	30 - 3'901 - 50	13 - 2'329 - 80	9 - 263 - 45	373 - 5'341 : - 1'230	143 — 20'582 — 11'519	139 - 31'130 - 20'395
Diphtheria Japanese encephalitis Measles Mumps Pertussis Polio Rubella Rubella	2 51 - 14 0 20	10 - 82 - 116 0 18	28 - 615 - 145 0 45	13 - 99 - 115 0 14	190 - 189 - 1'415 0 32	150 - 332 - 1'329 0 30	132 - 73 - 650 0 20	106 - 538 - 464 0 24	58 - 262 - 590 0	52 - 127 - 605 0 14	32 - 133 - 267 0	26 - 220 - 89	15 - 7 - 125	6 - 3 - 98	24 - 11'644 - 81	10 - 9'554 - 21	15 - 9'582 - 112	18 - 11'874 10'417 94 3	13 - 4'137 : - 24	13 - 2'869 - 20	30 - 3'901 - 50	13 - 2'329 - 80	9 - 263 - 45	373 - 5'341 : - 1'230	143 — 20'582 — 11'519	139 - 31'130 - 20'395
Diphtheria Japanese encephalitis Measles Mumps Pertussis Polio Rubella Rubella (CRS) Tetanus	2 51 - 14 0 20	10 - 82 - 116 0 18	28 - 615 - 145 0 45	13 - 99 - 115 0 14	190 - 189 - 1'415 0 32	150 - 332 - 1'329 0 30	132 - 73 - 650 0 20	106 - 538 - 464 0 24	58 - 262 - 590 0 11 49	52 - 127 - 605 0 14	32 - 133 - 267 0 20	26 - 220 - 89 0 -	15 - 7 - 125	6 - 3 - 98	24 - 11'644 - 81 0 -	10 - 9'554 - 21 0 -	15 - 9'582 - 112 0 -	18 — 11'874 10'417 94 3 1'154	13 - 4'137 : - 24 3 -	13 - 2'869 - 20 4 -	30 - 3'901 - 50 13 -	13 - 2'329 - 80 12 -	9 - 263 - 45 101 -	373 - 5'341 : - 1'230 15 -	143 — 20'582 — 11'519	139 - 31'130 - 20'395





#### Health Development and Outcomes among Provinces in Iran

R. Bahrami and M. Rezaei; Reaserch and Science Journalmof Kermanshah Medical University; year 19;2015



# **COVID** – 19


When,

How and

Why

the virus entered/identified?

## The initial status of COVID-19



# Controversy among stakeholders on

when and

How to respond

# How and why the initial policies changes over time and the extend to which they were politically motivated


- Initial reaction of policy makers and experts
- Ministry of Health, health experts, Parliament members, Military, Religious leader
- Quarantine or physical distance?
- Quality of data reporting?
- Vaccination?
- Budget allocation?

## The current situation of the COVID-19


Total reported death 137K

Total reported cases 7 M

#### Total Coronavirus Cases in Iran



#### Trend of COVID-19




# The current situation of the COVID-19 and Vaccination

• 1<sup>st</sup> dose: 75%

• 2<sup>nd</sup> dose: 66%

• 3<sup>rd</sup> dose: 27%



#### Case Studies

Lesson Learnt from other countries

#### Conclusion:

- Lack of trust
- Lack of transparency
- Unequal access
- Unsustainable policy and management
- Lack of involvement of experts in decision making process
- Less attention to the scientific priorities
- Prioritized politics and ideology